Table 3 Medications used to treat terminal pancreatic patients according to end-of-life care
Ranking | Inpatient palliative care (n = 276) | Acute hospital care (n = 276) | ||||
|---|---|---|---|---|---|---|
Drug class (ATC code) | n | % | Drug class (ATC code) | n | % | |
1 | Natural opium alkaloids (N02AA) | 233 | 84.4 | Solutions affecting the electrolyte balance (B05BB) | 268 | 97.1 |
2 | Solutions affecting the electrolyte balance (B05BB) | 221 | 80.1 | Solutions for parenteral nutrition (B05BA) | 223 | 80.8 |
3 | Propulsives (A03FA) | 152 | 55.1 | Propulsives (A03FA) | 200 | 72.5 |
4 | Contact laxatives (A06AB) | 146 | 52.9 | Plain sulfonamide diuretics (C03CA) | 198 | 71.7 |
5 | Benzodiazepine derivatives (N05CD) | 133 | 48.2 | Electrolyte solutions (B05XA) | 184 | 66.7 |
6 | Solutions for parenteral nutrition (B05BA) | 124 | 44.9 | Contact laxatives (A06AB) | 167 | 60.5 |
7 | Glucocorticoids (H02AB) | 123 | 44.6 | Cephalosporins (J01DA) | 167 | 60.5 |
8 | Plain sulfonamide diuretics (C03CA) | 118 | 42.8 | Phenylpiperidine derivatives opioids (N02AB) | 159 | 57.6 |
9 | Butyrophenone derivatives antipsychotics (N05AD) | 111 | 40.2 | Natural opium alkaloids (N02AA) | 156 | 56.5 |
10 | Magnesium compounds (A02AA) | 108 | 39.1 | Adrenergic and dopaminergic agents (C01CA) | 146 | 52.9 |